12 Amendments of Andreas GLÜCK related to 2020/2071(INI)
Amendment 84 #
Motion for a resolution
Recital C
Recital C
C. whereas the loss of European sovereignty and independence in the health sector is linked to the relocation of production, with 40% of medicinal end products marketed in the EU now originating in third countries; whereas the only way to save money is toEurope has a strong manufacturing footprint which should be incentivised, the supply chain relyies heavily on subcontractors to produce pharmaceutical raw materials in Asia, where labour costs and environmental standards are lower, with the result that 80% of active ingredients are manufactured outside the EU, mainly in China and India;
Amendment 103 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas it is equally important to protect and foster the existing production sites in the EU and strengthen the European research landscape;
Amendment 281 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls on the Commission and the Member States to take whatever action is neededto take the necessary actions to restore European health sovereignty and local pharmaceutical manufacturing, giving priority to essential and strategic medicines; calls on the Commission to map out existing production sites as well as potential production sites in the EU;
Amendment 321 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls on the Commission to draft an analysis on why medicine shortages occur before suggesting any regulatory measures and only subsequently present a strategy for preventing shortages of medicines and medical products in Europe and mitigate them where they occur;
Amendment 327 #
Motion for a resolution
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Calls on the Commission, in the context of the upcoming Pharmaceutical Strategy, to propose and implement an ambitious agenda to optimise the current regulatory framework in order to contribute to the prevention of medicine shortages by reducing the administrative burden both for the regulators and the industry, reflecting the evolution in technology as well as fostering greater economic resilience and therefore access to and availability of affordable medicines for patients;
Amendment 343 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Urges the Commission and the Member States to introduce tax and financial incentivescentives supporting the diversification of supply in return for appropriate commitments and to authorise state aid to encourage producers to locate their operations in Europe, from compound manufacturing to packaging and distribution; emphasises the strategic significance of this sector and the importance of investing in European companies, in the interests of resource diversification;
Amendment 507 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Recommends the introduction of centralised management to bring about greater transparency in the distribution chain and the creation of a European supply management unit tasked with developing a European strategy to prevent and resolve breaks in supplysupply disruptions;
Amendment 588 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Calls on the Commission and Member States to develop innovative and coordinated strategies and to step up exchanges of good practice in the area of stock management; considers that the European Medicines Agency (EMA) cshould be designated as the regulatory authority tasked with coordinating exchanges between the Member States to preventing shortages of essential medicines, with a correspondingly wider remit and more staff;
Amendment 615 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls for further invitations to tender to be issued at European level in an effort to counter shortages during a time of crisis, as has been done following the onset of the COVID-19 virus, with simplified procedures in the interests of improved response times;
Amendment 641 #
Motion for a resolution
Paragraph 18
Paragraph 18
18. Calls on the Commission to set up an innovative centralised digital platform for sharing information provided by national agencies and all stakeholders including manufacturers, wholesalers and pharmacists, regarding shortages of medicines and medical equipment; such a platform should be efficient, easy to work with and transparent; welcomes the introduction by the EMA of the SPOC and i-SPOC systems; calls for existing information systems to be improved so as to provide a clear overview of problemdemands, shortages and requirements in each Member State, with a view to preventing stockpiling;
Amendment 681 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Considers it essential to improve an early communication with healthcare professionals and patients on medicine availability through the use of innovative digital tools providing real-time data on the availability, location, quantity and price of a given medicine, in compliance with data protection legislation; recommends the inclusion of information for healthcare professionals on available alternatives;
Amendment 693 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Calls forto replace the paper leaflet with the implementation of an electronic product information notice to be drawn up in all the Union languages for everyleaflet in all languages for all the countries where the medicine on the EUis marketed, in order to facilitate sales ofmoving medicines between Member States; recommends the provision of more comprehensive information on the origin of medicineswithin the Single Market to prevent and mitigate a shortage;